Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma

The combination of lenvatinib and pembrolizumab may extend by more than 1 year the lives of patients with advanced melanoma who progress after immunotherapy, show ' important ' trial results.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news